A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

Cannot have received: allogeneic hematopoietic stem cell transplant

Previously received allogeneic hematopoietic stem cell transplantation

Cannot have received: autologous hematopoietic stem cell transplant

Exception: within 3 months before the first medication

Received autologous hematopoietic stem cell transplantation within 3 months before the first medication

Cannot have received: chemotherapy

Exception: within 4 weeks before the first medication

He has received chemotherapy and radiotherapy within 4 weeks before the first medication

Cannot have received: radiation therapy

Exception: within 4 weeks before the first medication

He has received chemotherapy and radiotherapy within 4 weeks before the first medication

Cannot have received: immune checkpoint inhibitor

Exception: within 12 weeks before the first medication

immune checkpoint inhibitor ... within 12 weeks before the first medication

Cannot have received: CAR-T cell therapy

Exception: within 12 weeks before the first medication

Chimeric Antigen Receptor T (CAR-T)-Cell Immunotherapy within 12 weeks before the first medication

Cannot have received: small molecule anti-tumor treatment

Exception: within 5 half-lives before the first medication

other small molecule anti-tumor treatments ... before the first medication are within 5 half-lives

Cannot have received: BCL2 inhibitor

previously received BCL-2 inhibitors